What question did this study set out to answer?

This study evaluates the prevalence and outcomes of infections in ANCA-associated vasculitis and identifies risk factors.

May 11, 2026Open Access

Infectious complications of ANCA-associated vasculitis: Description and associated outcome

Key Points

This study evaluates the prevalence and outcomes of infections in ANCA-associated vasculitis and identifies risk factors.
Retrospective monocentric study including 264 patients with AAV from 2004 to 2024.
Infections defined by hospitalization or need for anti-infectious therapy.
Follow-up until January 1, 2025.
Infection incidence was 43.9%, with respiratory infections being 49.1% and bacterial infections at 75.3%.
Anti-PR3 positivity identified as an independent risk factor (aOR = 2.0, p=0.03); methotrexate shown to be protective (aOR = 0.08, p=0.001).
Infections linked to increased risk of vasculitis relapses (aOR = 2.8, p=0.007) and cardiovascular events (aOR = 3.0, p=0.01).

Abstract

Introduction:In ANCA-associated vasculitis (AAV), both the disease and its treatments contribute to systemic complications, among which, infections represent a major cause of morbidity and mortality.This study aimed to evaluate the prevalence and prognosis of infectious complications in AAV, to identify associated risk factors, and to describe long-term outcomes.Methods: This retrospective monocentric study included patients followed in the Nephrology and Internal Medicine departments at Conception Hospital after a first episode or relapse of AAV between 2004 and 2024.Infection was considered if requiring hospitalization or an anti-infectious therapy.Follow-up was conducted until January 1 st , 2025.Results: Among 264 patients included, the incidence of infection was 43.9%, with respiratory infections accounting for 49.1% of cases and bacterial infections for 75.3%, mainly with gram negative bacillus.Infection episodes were significantly associated with age >65 years (p =0.02), hypertension (p=0.04),diabetes (p =0.01), a high Five-Factor Score (p =0.005), a high BVAS (p =0.03), anti-PR3 positivity (p =0.03), acute kidney injury (p=0.004),cyclophosphamide (p =0.05), and intravenous corticosteroid for induction (p =0.03).In multivariate analysis, anti-PR3 positivity (aOR = 2.0, p=0.03) was independent risk factors, whereas methotrexate appeared protective (aOR = 0.08, p=0.001).Infections were independently linked to vasculitis relapses (aOR = 2.8, p=0.007) and cardiovascular events (aOR 3.0, p =0.01).Survival analysis demonstrated a significant association between mortality and infection (HR 2.14 95%CI 1.59-2.91,p<0.001).Conclusion: Infections are frequent complications in AAV, and exert an independent impact on mortality.Anti-PR3 positivity increases infection risk, whereas methotrexate appears protective.

KI fragen

Bookmark

View Full Paper